Downloading...
Download

Atossa

Atossa Therapeutics due for a local correction. ATOSIt was a spectacular run for this stock, yet we seem to be at the end of the run. This is backed up by momentum divergences and dropping momentum overall. The latter is both on RSI and MACD. Indicator picture is more or less the same up to the daily chart. Our take on technical indicators is always secondary to the fractal picture of the markets. Anyway... pivoting down. We are not in the business of getting every prediction right, no one ever does. The Fibonacci targets going down are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:ATOSShort
by Rykin_Capital
ATOS mini TA with fib linesNot surprised that we fell hard after breaking the uptrend (green line) at $8, retested the line at $8.40 to perfection and then fell about 35% to current prices. What surprises me more is that the $5.66 support didn't hold and is now acting as a resistance zone. If we do break this mini resistance, I have no doubt that we will test the $6.60 fib region again. Else, I can see this stock trading between the $4.10 and $5.66 region for a few days/weeks. If it does go lower and hold the 4.10 support I'm a buyer again. Good luck to all holders, I'm sure we all know the potential of this company.
NASDAQ:ATOS
by metalhound
Here We Go (Again?) With ATOSThis is familiar territory with ATOS . Not only is there a very clear and significant support level on the chart, there's also a multi-year level of resistance the ATOS is sitting at right now. The biggest question is Now What? " Earlier this month, Atossa revealed data from a Phase 2 Endoxifen study in breast cancer. It met primary and secondary endpoints. The Phase 2 study was conducted on behalf of Atossa by Avance Clinical, a leading Australian CRO. Based on the results, the company also discussed its plan to apply to the FDA for approval to begin a clinical study in the US 'as soon as possible.' With meaningful results and potential for more clinical trials in the US, ATOS could be on the list of biotech penny stocks on Robinhood to watch this summer ." Quote Source: 7 Penny Stocks On Robinhood To Watch In June 2021
NASDAQ:ATOS
by PennyStocks101
13
ATOS - Triple Bottom with a Breakout?Set up looks great. Triple bottom, break out and retest of a diagonal resistance. I absolutely dislike stocks like this but I like the chart. Will there be a catalyst to move this? The only catalyst for this one is the recent FDA "safe to proceed" letter to continue ovarian cancer treatment. If it actually materializes, could see a run towards levels above. It will only move if it catches momo crowd, otherwise just another garbage stonk.
NASDAQ:ATOSLong
by bossmodetrader